This is a clinical study to investigate how well Biostate works in treatment of male patients
below the age of 12 years who have a clotting factor deficiency that is aggravated by the
development of antibodies. The antibodies are directed against the clotting factor that is
given for replacement therapy and usually make therapy unsuccessful. The treatment used in
this study is called immune tolerance therapy.